Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Open Access
- 3 August 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 13 (2) , 94-98
Abstract
Background: Radiolabeled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors. Objective: The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data. Methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas. Results: Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors. Conclusion: Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.Keywords
This publication has 29 references indexed in Scilit:
- PSMA Expression in Papillary Thyroid CarcinomaClinical Nuclear Medicine, 2016
- First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- In vivo visualization of prostate-specific membrane antigen in glioblastomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastasesCancer Cell International, 2014
- Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma MultiformeArchives of Pathology & Laboratory Medicine, 2011
- Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancersHuman Pathology, 2009
- Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human TissuesWorld Journal of Surgery, 2006
- Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancerGene, 2002